Biosense Webster, a Johnson & Johnson company, has received Food and Drug Administration approval for the CARTO® 3 cardiac electrophysiology system. Features of the device include magneto-electric localization of catheters, high speed 3D cardiac mapping, and a new central connection system for catheters and accompanying equipment.
ACL is a hybrid technology that allows for accurate catheter tip and curve visualization without spatial distortion. This helps the electrophysiologist to orient catheters with precision for diagnostic and therapeutic applications. The system can visualize up to five catheters simultaneously with clear distinction of all electrodes.
FAM is a leading-edge technology that quickly and accurately creates high-resolution, CT-like maps as quickly as an EP can move his or her catheter throughout the cardiac chamber. FAM technology also permits detailed visual enhancement of a specific area of interest within the heart.
Connection of Choice™ is enabled by the brand new Carto® System hardware configuration featuring a central connection point for all catheters and equipment while preserving the signal quality of intracardiac electrograms.
FAM is a leading-edge technology that quickly and accurately creates high-resolution, CT-like maps as quickly as an EP can move his or her catheter throughout the cardiac chamber. FAM technology also permits detailed visual enhancement of a specific area of interest within the heart.
Catheter connections have been re-designed for “plug-and-play” functionality and automatic catheter recognition. All of these enhancements have been developed to streamline and simplify workflow in the EP lab.Press release: Biosense Webster Receives FDA Clearance For The CARTO® 3 System…
Product page: CARTO 3 System…